Literature DB >> 2450180

Studies on neurotransmitter markers of the basal ganglia in Pick's disease, with special reference to dopamine reduction.

I Kanazawa1, S Kwak, H Sasaki, O Muramoto, T Mizutani, A Hori, N Nukina.   

Abstract

gamma-Aminobutyric acid (GABA), substance P and dopamine concentrations and choline acetyltransferase (ChAT) activity were measured in post-mortem cerebrocortical and basal ganglial areas of 14 controls and 4 patients with pathologically verified Pick's disease (1 classic case and 3 cases of the generalized form). GABA and substance P levels in the substantia nigra and the globus pallidus were generally decreased, corresponding to the moderate to severe loss of small neurones in the striatum. ChAT activities in the striatum varied from case to case, in proportion to various degrees of loss of large neurones in the striatum. These neurotransmitter abnormalities in Pick's disease were exactly the same as those in Huntington's disease. However, dopamine concentrations were markedly reduced in the striatum in Pick's disease, whereas striatal dopamine in Huntington's disease is reported to be increased. A dopamine reduction in the striatum of Pick's disease was more disproportionately prominent than expected for various degrees of nigral cell loss. This may be one of the important factors which prevents the generation of choreic movements in Pick's disease in spite of definite striatal atrophy similar to Huntington's disease.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2450180     DOI: 10.1016/0022-510x(88)90020-2

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  9 in total

1.  Selective loss of nigral neurons in Pick's disease: a morphometric study.

Authors:  T Uchihara; K Tsuchiya; K Kosaka
Journal:  Acta Neuropathol       Date:  1990       Impact factor: 17.088

Review 2.  Medical management of frontotemporal dementias: the importance of the caregiver in symptom assessment and guidance of treatment strategies.

Authors:  Gregory A Jicha
Journal:  J Mol Neurosci       Date:  2011-06-07       Impact factor: 3.444

3.  Management of frontotemporal dementia: targeting symptom management in such a heterogeneous disease requires a wide range of therapeutic options.

Authors:  Gregory A Jicha; Peter T Nelson
Journal:  Neurodegener Dis Manag       Date:  2011-04

Review 4.  A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia.

Authors:  Edward D Huey; Karen T Putnam; Jordan Grafman
Journal:  Neurology       Date:  2006-01-10       Impact factor: 9.910

5.  Striatopallidonigral degeneration in Pick's disease: a clinicopathological study of 41 cases.

Authors:  K Kosaka; K Ikeda; K Kobayashi; P Mehraein
Journal:  J Neurol       Date:  1991-06       Impact factor: 4.849

Review 6.  Frontotemporal lobar degeneration: epidemiology, pathology, diagnosis and management.

Authors:  Rachel E Seltman; Brandy R Matthews
Journal:  CNS Drugs       Date:  2012-10-01       Impact factor: 5.749

Review 7.  Pharmacotherapy for Neuropsychiatric Symptoms in Frontotemporal Dementia.

Authors:  Christine Le; Elizabeth Finger
Journal:  CNS Drugs       Date:  2021-08-24       Impact factor: 5.749

Review 8.  Neurotransmitter deficits from frontotemporal lobar degeneration.

Authors:  Alexander G Murley; James B Rowe
Journal:  Brain       Date:  2018-05-01       Impact factor: 13.501

9.  GABA and glutamate deficits from frontotemporal lobar degeneration are associated with disinhibition.

Authors:  Alexander G Murley; Matthew A Rouse; P Simon Jones; Rong Ye; Frank H Hezemans; Claire O'Callaghan; Polytimi Frangou; Zoe Kourtzi; Catarina Rua; T Adrian Carpenter; Christopher T Rodgers; James B Rowe
Journal:  Brain       Date:  2020-12-05       Impact factor: 13.501

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.